Key result
Melagatran/ximelagatran is noninferior to warfarin for stroke prevention and DVT treatment, though 6%-12% of patients develop asymptomatic elevated liver enzymes.
Why the study?
Is melagatran/ximelagatran effective and safe compared to warfarin or heparin-warfarin for stroke prevention in atrial fibrillation and venous thromboembolism management?
Population
Patients with non-valvular atrial fibrillation, deep vein thrombosis, or undergoing major orthopaedic surgery
Comparison
Melagatran/ximelagatran vs Warfarin or heparin-warfarin
Design
Review
Authors
Loading...
May offer monitoring-free anticoagulation in AF/VTE; leaves open hepatotoxicity questions for broader use.
Is melagatran/ximelagatran effective and safe compared to warfarin or heparin-warfarin for stroke prevention in atrial fibrillation and venous thromboembolism management?
Melagatran/ximelagatran offers an effective alternative to warfarin for anticoagulation without the need for monitoring, though it carries a risk of liver enzyme elevation.
Timothy Brighton (2004) conducted a review in Non-valvular atrial fibrillation, deep vein thrombosis, and venous thromboembolism. Melagatran/ximelagatran vs. Warfarin, heparin-warfarin was evaluated. Melagatran/ximelagatran is noninferior to warfarin for stroke prevention and DVT treatment, though 6%-12% of patients develop asymptomatic elevated liver enzymes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: